PHARMACOLOGY Flashcards

1
Q

Drug disposition commences with which of tge following pharmacokinetic principles?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion

A

DISTRIBUTION

Disposition: DME
Pharmacokinetics: ADME
Drug EliMInation: ME

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drug elimination commences with which of the following pharmacokinetic process?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion

A

METABOLISM

Drug Disposition= Drug Dstribution
Drug Elimination= MEtabolism
EliMination: ME

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

True of bioavailability
A. Rate and extent of drug distribution
B. Amount of drug in the blood stream
C. Rate and extent of drug clearance
D. 10% only for IM administered

A

AMOUNT OF DRUG IN THE BLOODSTREAM
Rate and extent on DRUG ABSORPTION
90% bioavailability IM
10% bioavailablity topical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

True of bioavailability
A. Applicable only to IV drugs
B. Reflects fraction of drugs metabolized
C. Always poor in orally administered drugs
D. Greatly affected by drug absorption

A

GREATLY AFFECTED BY DRUG ABSORPTION

Bioavailability= durgs absorbed/ in blood stream
Oral drugs have LESS biovailability, not poor

!!Beware ALWAYS and ONLY words!!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which of the following statements is correct:
In IV Route…
A. Drugs NOT absorbed, 100% bioavailability
B. Compared to Oral drugs which are poorly absorbed with 100% biovailability
C. Good absorption, 100% bioavailability
D. Depot effect

A

IV drugs ARE NOT ABSORBED because they go DIRECTLY blood stream. There is no LOSS od the drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Patient ingested 24 Aspirin tablets and developed hepatic encephalopathy. Blood needs to be alkalanized via IV NaHCO3. What is the basis of this management?
A. NaHCO3 traps aspirin in ionized form
B. NaHCO3 neutralizes free aspirin in the systemic circulation
C. NaHCO3 increases fraction of protein bound aspirin, reducing toxicity
D. NaHCO3 induces CYP450 enzyme in hepatocytes, accelerating elimination of the toxin

A

NaHCO3 TRAPS ASPIRIN IN IONIZED FORM

“Ionized trapping” based on Henderson Hassleback Equation, acid+basic –> ionized form –> excreted

EXCRETABLE: ionized/ non-lipid soluble/ polar (I NL P)
ABSORBABLE: non-ionized/ lipid soluble/ non-polar (non-lipd-non)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

In a case of sepsis, prompt antibiotic administration is needed. In these cases, a loading dose would be warranted. What is the basis for the computation of the loading dose?
A. Drug plasma concentration
B. eGFR and serum creatinine
C. Drug clearance
D. Volume distribution of a drug

A

VOLUME DISTRIBUTION OF A DRUG

amount of drug into tissue/body fluid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Phenobarbital was given to a patient on chronic warfarin. It is classified as:
A. Pharmacodynamic antagonist
B. Pharmacokinetic antagonist
C. Physiologic antagonist
D. Chemical antagonist

A

PHARMACOKINETIC ANTAGONIST

Phenobarbital is an ENZYME EINDUCER hece affects METABOLISM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pharmacologic drugs that has noth INTRINSIC ACTIVITY and AFFINITY:
A. Agonist
B. Antagonist
C. Synergist
D. None

A

AGONIST

Intrinsic activity- binding; leads to pharmacologic response
Affinity- ability to bind to a receptor; fits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pharmacologic drugs that has AFFINITY but NO INTRINSIC ACTIVITY:
A. Agonist
B. Antagonist
C. Synergist
D. None

A

ANTAGONIST

Intrinsic activity- binding; leads to pharmacologic response
Affinity- ability to bind to a receptor; fits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which of the following drugs has a narrow therapeutic window?
A. Diazepam
B. Aspirin
C. Digoxin
D. Bethacolol

A

DIGOXIN

Narrow therapeutic index drugs: WALA C PhePhe! VAs-THE-D!
Warfarin, Aminoglicosides, Lithium, Ampothericin B, Carbamazepine, PHEnytoin, PHEnobarbital, VAncomycin, THEophylline, Digoxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How many half lives needed to reach a steady state?
A. 2-3
B. 3-4
C. 4-5
D. 5-6

A

3-4 half lives to reach a steady state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Patient has acute live failure and is given Drug A which is a protein bound drug. Which of the following is true?
A. The drug will have no effect on patient
B. The drug will have a toxic effect on patient
C. The drug will have an enhanced effect on the patient
D. The drug will not be metabolized

A

The drug will have increased TOXICITY

Patient with liver disease is likely to have HYPOALBUMINEMIA.
Prontein= binds, not cross biomembranes= NO EFFECT, NOT EXCRETED
Low albumin= less protein= less binding= more effect/ toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

A target plasma theophylline concentration of 10mg/L is desired to relieve acute bronchial asthma in a patient. If the patient is a nonsmoker and otherwise normal except for asthma, mean clearance is 2.8L/hr. The drug is to be given as an IV infusion dosing interval is 12hrs. Determine the DOSING RATE and MAINTENANCE RATE.

A

Maintenance rate= Dosing rate x dosing interval (MR DR DI)
Dosing rate= Target conc x Clearance (DR TC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the preferred reliever across all steps in the stepwise approach in asthma management?
A. LABA
B. SABA
C. Methylxanthine
D. ICS+ Formoterol

A

ICS + Formoterol

Previously SABA due to ecenomic reasons but changed due to “SABA only treatment”. Inc in SABA= Dec in B2 receptors= reduced effectivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Measures potency of acid neutralizing quantity of 1N HCl in to be brought up to 3.5 pH in 15min.
A. pH moderating ability
B. Acid neutralizing capacity
C. pH potency
D. Alkalanizing potency capacity

A

Acid neutralizing capacity

17
Q

Match the ff H2 Antagonists: Histamine plus:
>FURAN RING, IMIDAZOLE RING, THIAZIDE RING
<CIMETIDINE, FAMOTIDINE/NIZATIDINE, RANITIDINE

A

H2 antagonists inhibit basal acid production and prandial acid decrease. Structures are based of on histamine and additional ring.

FURAN RING- Ranitidine
IMIDAZOLE RING- Cimetidine
THIAZIDE RING- Famotidine/Nizatidine

18
Q

Which of the following antacids may result to nephrolithiasis:
A. Aluminum Hydroxide
B. Sodium Bicarbonate
C. Calcium Carbonate
D. Magnesium Hydroxide

A

CALCIUM carbonate- Hypercalcemia

Antacids are weak bases that neutralize stomach.
Al H- constipation (Ala tae)
Mg H- diarrhea (Magtatae)
Sodium bicarb- worsens HTN (Na), milk alkali syndrome (metab alkalosis)

19
Q

Cell that secretes Intrinsic factor for Vit B12 absorption and protonated HCl.
A. Oxyntic cell
B. Mucus Neck cell
C. Chief cells
D. Enterochromafin-like cell

A

Oxyntic cell/ parietal cell: H
Mucus Neck cell: Bicarbonate
Chief cells/Zymogenic cell/Principal cell/ Peptic cell: PEPSINOGEN
Enterochromafin-like cell: HISTAMINE

20
Q

Which of the following factors decrease PUD:
A. Prostaglandin
B. NSAID
C. Pepsin
D. Smoking

A

PROSTAGLANDINS- gastroprotective

INCREASING FACTORS PUD: H Pylori, NSAID, Acidic agents, Pepsin, Pepsin, Smoking

DECREASING FACTORS: Mucus production, Buffers, Blood flow, prostaglandin

21
Q

Patient with PUD has history of stroke and myocardial infarction and is maintained on CLOPIDOGREL. Which gastrointestinal drug is contraindicated?
A. Bismuth salts
B. Omeprazole
C. Ranitidine
D. Metoclopromide

A

Omeprazole is a CYP inhibitor, Clopidogrel CYP activated.

Using omeprazole will deactivate clopidogrel and predispose patient to MI or stroke.

22
Q

Gastrointestinal drug that has antimicrobial property:
A. Cimetidine
B. Bismuth Salicylate
C. Erythromycin
D. Methylcellulose

A

BISMUTH salts: 1) protective coating 2) stimulate mucosal coat 3) ANTIMICROBIAL

23
Q

What GI drug will cause black stool and black gums?
A. Docusate salts
B. Bismuth Salicylates
C. Magnesium sucralfate
D. Bismuth Subcitrate

A

BISMUTH SUBCITRATE- has metal coomponent

24
Q

Patient with GERD uses Betanechol. Possible adverse reactions:
A. Decreased gastric motility
B. May worsen hypertension
C. Bradycardia
D. Extrapyramidal symptoms

A

Inhibitors of Gastric motility:

Betanechol is a CHOLINERGIC AGONIST (rest and digest | Parasympathetic). SE: DUMBELS: Diaphoresis, Urination, Miosis, Bradycardia, Emesis, Lacrimation, Salivation

25
Q

D2 antagonist drug that increases gastric motility causes diarrhea due to release of MOTILIN.
A. Domperidone
B. Erythromycin
C. Metoclopromide
D. Neostigmine

A

ERYTHROMYCIN: diarrhea, pain on injection site

26
Q

Treatment for gastroparesis that may cause hyperprolactenemia leading to galactorrhea.
A. Metoclopromide
B. Misoprostol
C. Subcitrate
D. Domperidone

A

METOCLOPROMIDE: extrapyramidal symptoms
-crosses BBB affects area postrema as antiemetic, may cause EPS
-Endocrine side effect > Galactorrhea due to hyperprolactenemia

27
Q

Treatment for gastroparesis that is also for stimulation of postpartum lactation.
A. Metoclopromide
B. Misoprostol
C. Subcitrate
D. Domperidone

A

DOMPERIDONE- does NOT cross BBB as compared to METOCLOPROMIDE

28
Q

Which would increase both gastric motility and gastric acid?
A. Dopamine
B. Acetylcholine
C. Gastrin
D. B and C

A

Increases gastric motility: Ach, Gastrin, Motility
Increases gastric acid: Ach, Gastrin
Inhibits motility: Dopamine “D” gumagalaw, inhibitory

29
Q

The only laxative that can be used for chronic constipation.
A. Glycerin
B. Docusate salts
C. Psyllium
D. Bisacodyl

A

Psyllium- BULK FORMING, absorbs water, only for CHRONIC

Docusate salts- SURFACTANT laxatives, reduces tension, facilitates water penetration to poop
Bisacodyl- STIMULANT LAXATIVE